[Skip to Content]
[Skip to Content Landing]
November 10, 1993

Psychotropic Medications During Pregnancy: Risk to the Fetus

Author Affiliations

University of Florida Gainesville

JAMA. 1993;270(18):2177. doi:10.1001/jama.1993.03510180047018

To the Editor.  —I was excited to read the article by Pastuszak et al1 reporting on a prospective study of 128 women who took therapeutic doses of fluoxetine during their first trimester of pregnancy compared with the pregnancy outcome of two matched groups of women exposed to either nonteratogens or tricyclic antidepressants. Rates of major congenital malformations were similar for the three groups.This prospective study follows close on the heels of two studies reported in Lancet in 1992. Jacobson et al2 reported in a prospective study the pregnancy outcome after lithium exposure during the first trimester of pregnancy, and Bergman et al3 published the results of a study of exposure to benzodiazepines during fetal life using a retrospective approach. In the first study,2 women taking an average of 927 mg of lithium were compared with a control group of pregnant women who were taking drugs